Results 71 to 80 of about 82,211 (293)

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Obinutuzumab-induced acute thrombocytopenia and leukopenia in ANCA-associated glomerulonephritis: case report and literature review

Frontiers in Immunology
Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity. It is widely used in B-cell malignancies and is increasingly being explored in autoimmune diseases such as lupus nephritis. The main
Yiming Jin, Yiqi Huang, Xiaomiao He
doaj   +1 more source

Cytopenia occurrence in kidney transplant recipients within early post-transplant period

Journal of Research in Pharmacy Practice, 2017
Objective: This study assessed incidence, severity, and time to occurrence of drug-induced leukopenia/thrombocytopenia within 1st month after kidney transplantation.
Atefeh Jafari, Parisa Najivash, Mohammad-Reza Khatami, Simin Dashti-Khavidaki   +3 more
doaj   +1 more source

Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study) [PDF]

, 2013
This prospective, multicenter, single-arm, open-label Phase III study aimed to evaluate the efficacy and safety of Privigen (R) (10% liquid human intravenous immunoglobulin [IVIG], stabilized with l-proline) in patients with chronic inflammatory ...
Bauhofer, Artur, De Bleecker, Jan, Kamienowski, Jerzy, Léger, Jean-Marc, Merkies, Ingemar SJ, Mielke, Orell, Robberecht, Wim, Saarela, Mika, Shebl, Amgad, Sommer, Claudia, Stelmasiak, Zbigniew, Tackenberg, Björn, Zenker, Othmar   +12 more
core   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Immuno-Haematological Abnormalities of HIV-Infected Patients Before and After Initiation of Highly Active Antiretroviral Therapy in the Antiretroviral Therapy Clinics of Six Health Facilities at Dessie Town, Northeast Ethiopia

Journal of Blood Medicine, 2022
Mihret Tilahun,1 Alemu Gedefie,1 Endris Ebrahim,1 Abdurahaman Seid,1 Abdurrahman Ali,1 Agumas Shibabaw,1 Melaku Ashagrie Belete,1 Mesfin Fiseha,1 Melkam Tesfaye,1 Hussen Ebrahim,1 Admasu Abera2 1Department of Medical Laboratory Sciences, College of ...
Tilahun M, Gedefie A, Ebrahim E, Seid A, Ali A, Shibabaw A, Belete MA, Fiseha M, Tesfaye M, Ebrahim H, Abera A   +10 more
doaj  

Triplet Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Patients with Recurrent or Refractory Non-small Cell Lung Cancer [PDF]

, 2010
We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively.
Fujimoto, Nobukazu, Fujiwara, Yoshiro, Kiura, Katsuyuki, Tabata, Masahiro, Takigawa, Nagio, Tanimoto, Mitsune, Toyooka, Shinichi, Ueoka, Hiroshi, Umemura, Shigeki   +8 more
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer [PDF]

, 2012
Background: Data from meta-analyses have shown taxane-containing therapies to be superior to anthracycline-based treatments for high-risk breast cancer. Patients and Methods: The ADEBAR trial was a multicenter phase Ill trial in which patients with lymph
Aivazova-Fuchs, Viktoria, Andergassen, Ulrich, Annecke, Katja, Augustin, Doris, Friese, Klaus, Harbeck, Nadia, Hepp, Philip, Janni, Wolfgang, Jückstock, Julia K., Kiechle, Marion, Mohrmann, Svjetlana, Rack, Brigitte, Salmen, Jessica, Schönherr, Alexandra, Simon, Wolfgang, Wischnik, Arthur, Zwingers, Thomas   +16 more
core   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source